Asahi Kasei Therapeutics receives FDA approval for oral HSV treatment

Key Takeaways

  • Herpes treatment approved: Cary-based Asahi Kasei Therapeutics received FDA approval for HOVILPRI (pritelivir) to treat herpes simplex virus (HSV) infection in immunocompromised adults 
  • Novel treatment: The oral medicine is the first FDA-approved treatment for refractory mucocutaneous HSV lesions with a novel mechanism of action in nearly 30 years 
  • More effective: In a Phase 3 clinical trial, HOVILPRI was more effective than the comparison treatments at healing lesions

Asahi Kasei Therapeutics Inc., the global specialty pharmaceutical business of Tokyo-based Asahi Kasei, with U.S. and European business headquarters in Cary, North Carolina, has received U.S. Food and Drug Administration (FDA) approval for HOVILPRI (pritelivir) 100 mg tablets to treat refractory mucocutaneous lesions caused by herpes simplex virus (HSV) infection in immunocompromised adults.

HOVILPRI is a novel helicase-primase inhibitor taken orally, providing a non-intravenous treatment option for certain immunocompromised adults with refractory HSV infection. The drug previously received Fast Track and Breakthrough Therapy designations from the FDA. The agency also granted Priority Review to the company’s New Drug Application (NDA).AK logo

“[The] approval delivers the first FDA-approved treatment for refractory mucocutaneous HSV lesions with a novel mechanism of action in nearly 30 years and marks an important advancement for immunocompromised adults,” said Stacy Wheeler, chief executive officer of Asahi Kasei Therapeutics in the U.S. and Europe. “HOVILPRI offers a new oral treatment option for adult patients with a persistent, difficult-to-treat disease.”

In healthy adults, HSV infections often cause no symptoms or only mild illness. However, in people with weakened immune systems — including transplant recipients and people living with HIV, cancer, or certain autoimmune or inflammatory conditions — infections can occur more often and cause more severe illness.

Refractory HSV infections — those that do not improve with standard antiviral treatment — can lead to persistent sores affecting the skin and mucous membranes. Some HSV strains develop mutations that make them less responsive to drugs such as acyclovir, which rely on a viral enzyme to become active. When standard treatments fail, alternatives have often required intravenous administration, creating additional challenges for patients and healthcare providers.

HOVILPRI works differently from existing antiviral drugs by blocking two viral proteins involved in HSV replication. This offers a different treatment approach for infections that do not respond to standard therapies.

The approval of HOVILPRI reflects years of clinical research in refractory HSV and reinforces our commitment to advancing scientifically differentiated medicines for patients whose conditions remain difficult to treat.

— Carl Kraus, chief medical officer, Asahi Kasei Therapeutics

Backed by clinical data

The FDA approval is supported by results from PRIOH-1 Part C, the pivotal Phase 3 trial in immunocompromised adults with mucocutaneous HSV infection that was refractory, with or without documented resistance, to acyclovir, valacyclovir, or famciclovir.

The trial showed that HOVILPRI was more effective than the comparison treatments and was also associated with fewer adverse reactions. By day 28, 63% of participants treated with HOVILPRI had achieved complete healing, compared with 34% of those receiving other treatments. 

“Refractory HSV can be a serious clinical challenge for immunocompromised adults, a population with limited treatment options,” said Carl Kraus, chief medical officer at Asahi Kasei Therapeutics. “The approval of HOVILPRI reflects years of clinical research in refractory HSV and reinforces our commitment to advancing scientifically differentiated medicines for patients whose conditions remain difficult to treat.” 

HOVILPRI was developed by Germany-based AiCuris Anti-infective Cures AG, which was acquired in April 2026 by Asahi Kasei through its U.S. subsidiary, Veloxis Pharmaceuticals, headquartered in Cary. Veloxis, which has an established commercial presence in transplant medicine, is now part of Asahi Kasei Therapeutics, the company's global pharmaceutical business. 

The treatment is expected to become available in the United States before the end of 2026.

Nancy Lamontagne, NCBiotech Writer
scroll back to top of page